vision study
April 16, 2020 No Comments
177Lu-PSMA-617 radioligand therapy in mCRPC – VISION phase 3 trial The results from the “ProPSMA” Study, that was recently published in JAMA Oncology by Prof.
Menu
Menu
177Lu-PSMA-617 radioligand therapy in mCRPC – VISION phase 3 trial The results from the “ProPSMA” Study, that was recently published in JAMA Oncology by Prof.
The “proPSMA” study results proved the superiority of 68Ga-PSMA imaging over conventional imaging with CT and Bone Scan in Prostate Cancer Results from a randomised
On October 10, 2019, the FDA approved the use of 18F-DOPA in positron emission tomography to visualize dopaminergic nerve terminals in the striatum for the
Carrier Added (CA) and Non-Carrier Added (NCA) Production of 177-Lu 177-Lu is a fully synthetic isotope. there are 2 ways to produce 177-Lu: The direct route
For decades, physicians and patients knew three classic treatments for cancer: Surgery Chemotherapy Radiation therapy New times have come, and new therapies are available like:
Innovative treatment for metastatic prostate cancer with 177-Lu-PSMA. Prostate cancer is the most common cancer in older men (over 50) and the second cause of
Get in touch…
